Table 1.
Baseline characteristics of 54 patients with stage T1, high grade, bladder tumors treated with intravesical Bacillus Calmette-Guérin immunotherapy
| Variable | Value* | ||||
|---|---|---|---|---|---|
| Sex (%) | Male | 47 (87) | |||
| Female | 7 (13) | ||||
| Median age years (IQR) | 73 (61,81) | ||||
| Smoking status (%) | Former/ Never | 42 (78) | |||
| Current | 12 (22) | ||||
| Tumor size (n=53, %) | ≤3cm | 28 (53) | |||
| >3cm | 25 (47) | ||||
| Tumor number (%) | Single | 35 (65) | |||
| Multiple | 19 (35) | ||||
| Recurrent tumor (%) | Yes | 5 (9) | |||
| No | 49 (91) | ||||
| Presence of CIS (%) | Yes | 2 (4) | |||
| No | 52 (96) | ||||
| EORTC risk score for recurrence | 0 | 0 (0) | |||
| 1–4 | 16 (30) | ||||
| 5–9 | 36 (67) | ||||
| 10–17 | 2 (4) | ||||
| EORTC risk score for progression | 0 | 0 (0) | |||
| 2–6 | 0 (0) | ||||
| 7–13 | 42 (78) | ||||
| 14–23 | 12 (22) | ||||
| RestagingTURBT(%) | Yes | 16 (30) | |||
| No | 38 (70) | ||||
| Maintenance BCG Treatment (%) | Yes | 37 (69) | |||
| No | 17 (31) | ||||
| Mean percent HSP expression (SD) | HSP60 | 31 ± 36 | |||
| HSP70 | 56 ± 44 | ||||
| HSP90 | 87 ± 28 | ||||
| Median percent HSP expression (IQR) | HSP60 | 15 (0,50) | |||
| HSP70 | 80 (0, 100) | ||||
| HSP90 | 100 (100, 100) | ||||
IQR = interquartile range; CIS = carcinoma in situ; EORTC = European Organization for Research and Treatment of Cancer; TURBT = transurethral resection of bladder tumor; BCG = Bacillus Calmette-Guérin; HSP = heat shock protein; SD = standard deviation.
*
Represents number of patients unless noted otherwise.